OTTAWA, Ontario, Feb. 22, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the completion of the sale of its shares of GrowPros MMP Inc. (“GrowPros”) to North Bud Farms Inc. (the “Purchaser” or “North Bud”) as previously announced in Tetra’s December 21st, 2017 press release.
Tag Archives: Ottawa
New Practice Resource: Medical Cannabis Evidence Guide
OTTAWA, Feb. 15, 2018 /Weed Wire/ — As part of its ongoing efforts to provide Canadian pharmacists with practice tools and resources, CPhA has developed a new medical cannabis evidence guide.
Ontario Selects Shopify to Run Mobile and Online Cannabis Sales
With Canadian cannabis legalization slated to commence this summer, Ontario has been proactive in its preparations, being the first province to issue its market regulations and now announcing a partnership with a popular ecommerce platform based in Ottawa to run mobile and online cannabis sales in the province.
Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
OTTAWA, Ontario, Feb. 5, 2018 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company’s PPP001 prescription smokable dried cannabis product.
Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis
OTTAWA, Ontario, Jan. 29, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.
Statement from Health Canada: Physical Security Requirements for Producers of Cannabis for Medical Purposes
OTTAWA, Ontario, Jan. 25, 2018 /Weed Wire/ – Health Canada is introducing two targeted changes to the physical security requirements under the Access to Cannabis for Medical Purposes Regulations (ACMPR) that must be respected by licensed producers (LP) of cannabis for medical purposes.
Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)
OTTAWA, Ontario, Jan. 16, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.
Cannabis Canada Association Announces Leadership Transition
OTTAWA, Ont., Jan. 4, 2018 /Weed Wire/ — The Board of Directors of Cannabis Canada Association (“Cannabis Canada”) today announced the departure of Colette Rivet from her position of Executive Director and the appointment of Allan Rewak as Acting Executive Director, while a comprehensive search for a permanent replacement is conducted.
Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary
OTTAWA, Ontario, Jan. 2, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement”) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors”).
Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and its Late Stage ACMPR Application
OTTAWA, Ontario, Dec. 21, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with a private Canadian corporation (the “Purchaser”) and has started a transaction to monetize GrowPros (GrowPros MMP Inc., Tetra’s wholly-owned subsidiary) (the “Potential Transaction”), to allow Tetra to focus its activities on the drug development and its clinical trials of its pharmaceutical business.
Canada’s Finance Ministers Reach Agreement on Cannabis Taxation
OTTAWA, Ontario, Dec. 20, 2017 /Weed Wire/ — Finance Minister Bill Morneau today issued the following statement…
Many Cannabis Users Aren’t Convinced Marijuana Causes Impaired Driving
A new Health Canada survey shows that Canadian cannabis users are hazy on the risks of driving while under the influence of the drug.
Health Canada Releases First Snapshot of Cannabis Use in Canada
OTTAWA, Ontario, Dec. 19, 2017 /Weed Wire/ — Between March and May 2017, Health Canada asked 9,215 Canadians about their knowledge, behaviours and attitudes towards cannabis use, including driving behaviours after consuming cannabis.
Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC
OTTAWA, Ontario, Dec. 13, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics.
Finance Ministers Reach Agreements on Behalf of All Canadians
OTTAWA, Ont., Dec. 11, 2017 /Weed Wire/ — Canada works best when governments work collaboratively to take actions that are in the interest of all Canadians, strengthen the middle class and help those working hard to join it. Federal, provincial and territorial Finance Ministers met today in Ottawa to build on their productive partnership, discuss issues that are top of mind for Canadians, and make further progress on important joint priorities.
Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony
OTTAWA, Ontario, Dec. 6, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, is pleased to announce that Tetra opened the Toronto Stock Exchange (“TSX”) yesterday at a ceremony to recognize the listing and trading of Tetra, which began on August 16th 2017 under the symbol TBP.
Sundial Joins Cannabis Canada Association
OTTAWA, Ontario, Dec. 06, 2017 /Weed Wire/ — Cannabis Canada Association is pleased to announce Sundial Growers Inc. (“Sundial”) as the association’s newest member.
Don’t Drive High: Public Awareness Campaign Launches Today
OTTAWA, Ontario, Dec. 5, 2017 /Weed Wire/ – Today, the Honourable Ralph Goodale, Minister of Public Safety and Emergency Preparedness, launched the Government of Canada’s drug-impaired driving public awareness campaign to communicate to Canadians the risks associated with driving under the influence of cannabis and other drugs.
CCI Appoints Mr. Maurizio Calconi as Vice President for CCI Staffing Solutions, a division of Cannabis Compliance Inc.
OTTAWA, Ontario, Dec. 4, 2017 /Weed Wire/ – Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce the appointment of Mr. Maurizio Calconi to the CCI team as VP of CCI’s Staffing Solutions division.
CCI and NAC Announce Manitoba Tender Intentions
OTTAWA, Ontario, Dec. 4, 2017 /Weed Wire/ – Cannabis Compliance Inc. (“CCI”) is pleased to announce that it is working with National Access Cannabis Corp. (“NAC”), providing technical services in connection with NAC’s anticipated proposal to the Manitoba Request for Proposal for Retail Cannabis stores (RFP 10QGET-CRS-2017) (the “RFP”) due December 22, 2017.
Tetra Bio-Pharma’s Business Model and Commercialization Strategy In Line with the Canadian Government’s Proposed Approach to the Regulation of Cannabis
OTTAWA, Ontario, Nov. 22, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government’s Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model, and that the company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets.
Pharmacists Disappointed with Proposed Cannabis Regulations, Concerned with Impact to Medical Cannabis Patients
OTTAWA, Ontario, Nov. 22, 2017 /Weed Wire/ — The Canadian Pharmacists Association (CPhA) is disappointed that the federal government’s proposed regulatory approach to cannabis continues to miss the mark on several key issues, displaying an ongoing lack of concern for medical cannabis patients.
Health Canada Launches Public Consultation on Proposed Approach to the Regulation of Cannabis
OTTAWA, Ont., Nov. 21, 2017 /Weed Wire/ — The current approach to cannabis does not work. Earlier this year, the Government of Canada introduced Bill C-45, the proposed Cannabis Act, to legalize, strictly regulate and restrict access to cannabis. Bill C-45 aims to keep cannabis out of the hands of Canadian youth and the profits away from criminals and organized crime.
Statement on the Government of Québec’s plan for the Regulation of Cannabis
OTTAWA, Ontario, Nov. 21, 2017 /Weed Wire/ — Cannabis Canada, and the licensed producers of medical cannabis that it represents, share Province’s commitment to ensuring adult Quebecers have access to safe, regulated cannabis products and support the Government’s decision to make clear its intentions regarding the distribution and retail of adult-use cannabis.
Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria
OTTAWA, Ontario Nov. 16, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps(TM), unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).
Statement on the Government of Canada’s Approach to Cannabis Taxation
OTTAWA, Ontario, Nov. 14, 2017 /Weed Wire/ — Cannabis Canada, and the licensed producers of medical cannabis it represents, share the Government of Canada’s commitment to regulating and restricting access to cannabis to keep it out of the hands of youth, and the profits out of the hands of criminals.
Government of Canada Announces Consultation on Proposed Excise Duty Framework for Cannabis Products
OTTAWA, Ontario, Nov. 14, 2017 /Weed Wire/ — The Department of Finance Canada today published for consultation a proposed excise duty framework for cannabis products. The proposed level of taxation is intended to keep prices low to eliminate the black market, as discussed at the Finance Ministers Meeting last June.
Health Canada hosts Partnership Symposium on Cannabis Public Education and Awareness in Ottawa
OTTAWA, Ontario, Nov. 10, 2017 /Weed Wire/ — Today, Health Canada hosted a one-day public education symposium with approximately 90 representatives from federal, provincial and territorial governments, Indigenous groups, and health and other partner organizations that play a role in raising awareness and educating Canadians about the health and safety risks of cannabis use.
Government of Canada Announces Consultation on Proposed Excise Duty Framework for Cannabis Products
OTTAWA, Ont., Nov. 10, 2017 /Weed Wire/ — The current approach to cannabis is not working, and the Government of Canada is committed to legalizing, regulating and restricting access to cannabis to keep it out of the hands of kids, and profits out of the hands of criminals.
Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device
OTTAWA, Ontario, Nov. 9, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps(TM) inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps(TM).
Government of Canada to Invest in Cannabis Education and Awareness
OTTAWA, Ontario, Oct. 31, 2017 /Weed Wire/ — The Government of Canada introduced legislation to legalize, strictly regulate and restrict access to cannabis to keep it out of the hands of Canadian youth and the profits from criminals and organized crime.
Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis
OTTAWA, Ontario, Oct. 26, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.
Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image
OTTAWA, Oct. 19, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).
Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR
OTTAWA, Ontario, Oct. 18, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR).
Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb
OTTAWA, Ontario, Oct. 12, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market – Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident.
Tetra Bio-Pharma Selected to Present at Prestigious BIO Investor Forum In San Francisco October 17-18
OTTAWA, Ontario, Oct. 4, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel.
Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market
OTTAWA, Ontario, Sept. 28, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis.
Tetra Bio-Pharma to Engage in Co-Development and Distribution Partnership With Major Healthcare Specialty Distributor
OTTAWA, Ontario, Sept. 20, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.
Ottawa Vaad Certifies First Kosher Medical Marijuana in Canada
A Quebec company has received the first kosher certification granted to medical marijuana products in Canada.
Cannabis Compliance Forms A Strategic Partnership For Secure Transport Of Cannabis
TORONTO, Sept. 19, 2017 /Weed Wire/ – Cannabis Compliance Inc., (CCI) of Toronto, Ontario, Canada, is pleased to announce the formation of a strategic partnership with 3|Sixty Secure Corp. of Ottawa, Ontario, Canada, to provide the ultimate in security, transport and compliance for Canadian medical marijuana.
Canadian Cannabis Legalization Hearings Happening in Parliament Right Now
On Sept. 11, 2017, Canada’s House of Commons health committee returned to Parliament Hill in Ottawa to begin the first of five full-day hearings on Canadian cannabis legalization.
Cannabis Canada Statement on the Government of Ontario’s Announcement on the Province’s Approach to the Federal Legalization of Cannabis
OTTAWA, Ont., Sept. 8, 2017 /Weed Wire/ — Cannabis Canada, and the licenced producers of medical cannabis that it represents, share the Province’s commitment to ensuring adult Ontarians have access to safe, regulated cannabis products and support the Government’s decision to make clear its intentions regarding the distribution and retail of recreational cannabis.
Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference – BioPharm America
OTTAWA, Ontario, Sept. 8, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.
Tetra Bio-Pharma to Benefit from Intellectual Properties Created within the Cannabis Health Research Chair from the University of New Brunswick
OTTAWA, Ontario, Aug. 31, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that it will benefit from the intellectual property (IP) created within the cannabis health research Chair (The Chair) from the University of New Brunswick (UNB).
Tetra Bio-Pharma Strengthens its Management Team in Preparation for the Initiation of its Commercial Activities
OTTAWA, Ontario, Aug. 29, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today announced that it has strengthened its management team in preparation for the initiation of its commercial activities with the appointments of Dr. Anne-Sophie Courtois to the position of Vice President, Marketing effective immediately and Mr. Bernard Lessard to the position of Chief Financial Officer (CFO), effective September 18, 2017.
Tetra Bio-Pharma’s Clinical Research Partner, Altasciences, offers Innovative Cannabis Research Solutions
OTTAWA, Ontario, Aug. 28, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) and Altasciences are pleased to share that they are in the final stages of completing the world’s first safety and tolerability study on a cannabis extract being developed as a new chemical entity for approval by the FDA and Health Canada as a drug.
Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange
OTTAWA, Ontario, Aug. 16, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (” Tetra ” or the ” Company “) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE).
CannaRoyalty Investee, AltMed, Partners with Established Cultivator; Awarded Florida Medical Marijuana License
OTTAWA, Onatario, Aug. 2, 2017 /Weed Wire/ — CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) (“CannaRoyalty” or the “Company”), a fully integrated, active investor and operator in the legal cannabis industry, is pleased to announce that one of its investee companies, AltMed, has agreed to combine its Florida operations with Plants of Ruskin Inc. (“Ruskin”), a multi-generational Florida cultivator, to form AltMed Florida.
Tetra Bio-Pharma Announces Stock Option Grant to CEO
OTTAWA, Ontario, July 25, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company.
Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics
OTTAWA, Ontario, July 19, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.